Cell-Selective Therapies for Coronary Artery Disease
冠状动脉疾病的细胞选择性疗法
基本信息
- 批准号:10543849
- 负责人:
- 金额:$ 48.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-15 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:Adenovirus VectorAffectAnimal ModelApolipoprotein EArterial Fatty StreakAtherosclerosisBiologicalBlood VesselsCannulationsCardiovascular DiseasesCardiovascular systemCarotid ArteriesCategoriesCause of DeathCell physiologyCellsCessation of lifeClinicalClinical ResearchCoronary ArteriosclerosisCoronary arteryCyclin-Dependent Kinase InhibitorDevelopmentEndothelial CellsEndotheliumEpidemicEventExhibitsFoundationsFunctional disorderGoalsHeartHumanHyperplasiaIncidenceInfectionInflammationInflammatory InfiltrateInjuryInterleukin-1 betaInterventionKnock-outLipidsMessenger RNAMicroRNAsModelingMusOryctolagus cuniculusPenetrationPeptidesPharmaceutical PreparationsPhysiologyProteinsRattusRecurrenceRegional PerfusionResistanceSafetySiteSmall Interfering RNASmooth Muscle MyocytesTechnologyTestingTherapeuticThrombophiliaThrombosisTimeToxic effectTranslatingUntranslated RegionsVascular Endothelial CellVascular Smooth MuscleVenouscyclin-dependent kinase inhibitor 1Bdesigndisabilityefficacy evaluationendonucleaseex vivo perfusionfemoral arteryhealinghuman tissuemouse modelnanoparticlenanoswitchnanotherapeuticnanotherapynovelnovel strategiesoverexpressionpersonalized medicinepharmacologicpreclinical studyprotein expressionrecombinant virusresponserestenosisself assemblytooltranslational potentialtreatment strategyuptakevascular smooth muscle cell proliferation
项目摘要
Atherosclerotic cardiovascular disease (CVD) represents a serious affliction affecting millions globally. Despite
recent advances in pharmacological and percutaneous interventions, CVD remains the leading cause of death
and disability in the world. One of the main therapeutic challenges facing atherosclerotic CVD is the delivery of
therapies to the atherosclerotic plaque that target the specific cells which contribute to its formation, while
protecting the endothelium. Vascular endothelial cells provide crucial protection against lipid uptake,
inflammation and thrombosis. We hypothesize that cell-selective therapy that inhibits infiltration of inflammatory
cells and proliferation of vascular smooth muscle cells, while protecting endothelia cell function will be effective
in combating CVD and thrombosis. To achieve this goal, we will develop a novel miRNA switch that combines
synthetically modified mRNA with miRNA target site. As a delivery platform we will utilize the cationic amphipathic
cell-penetrating peptide that forms a self-assembled, compacted, nanoparticle when mixed with synthetic mRNA.
Moreover, to increase the targeting of inflammation in the atherosclerotic plaque, we will combine the miRNA
switch together with siRNA targeting IL1-β to generate nanoparticles using the same cationic amphipathic cell-
penetrating peptide. In two specific aims, we will test 1) the efficacy of this cell-selective nanotherapy to inhibit
atherosclerosis and restenosis after percutaneous intervention, while protecting EC to reduce thrombosis; and
2) the translational potential of the miRNA switch nanotherapy in viable, isolated human coronary arteries.
Completion of the aims will provide the foundation for the development of a novel category of biological drugs
that can accommodate the advent of personalized medicine and will advance the treatment of cardiovascular
disease.
动脉粥样硬化性心血管疾病(CVD)是影响全球数百万人的严重疾病。尽管
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hana Totary-Jain其他文献
Hana Totary-Jain的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hana Totary-Jain', 18)}}的其他基金
MicroRNA-Based, Cell-Selective Therapy for Coronary Artery Disease
基于 MicroRNA 的冠状动脉疾病细胞选择性疗法
- 批准号:
9474655 - 财政年份:2015
- 资助金额:
$ 48.6万 - 项目类别:
Cell-Selective Therapies for Coronary Artery Disease
冠状动脉疾病的细胞选择性疗法
- 批准号:
10323294 - 财政年份:2015
- 资助金额:
$ 48.6万 - 项目类别:
MicroRNA-Based, Cell-Selective Therapy for Coronary Artery Disease
基于 MicroRNA 的冠状动脉疾病细胞选择性疗法
- 批准号:
9268806 - 财政年份:2015
- 资助金额:
$ 48.6万 - 项目类别:
MicroRNA-Based, Cell-Selective Therapy for Coronary Artery Disease
基于 MicroRNA 的冠状动脉疾病细胞选择性疗法
- 批准号:
9110298 - 财政年份:2015
- 资助金额:
$ 48.6万 - 项目类别:
MicroRNA Detargeting Novel Therapy for Coronary Artery Disease
MicroRNA 脱靶治疗冠状动脉疾病的新疗法
- 批准号:
8838234 - 财政年份:2013
- 资助金额:
$ 48.6万 - 项目类别:
MicroRNA Detargeting Novel Therapy for Coronary Artery Disease
MicroRNA 脱靶治疗冠状动脉疾病的新疗法
- 批准号:
8788329 - 财政年份:2013
- 资助金额:
$ 48.6万 - 项目类别:
MicroRNA Detargeting Novel Therapy for Coronary Artery Disease
MicroRNA 脱靶治疗冠状动脉疾病的新疗法
- 批准号:
8306029 - 财政年份:2011
- 资助金额:
$ 48.6万 - 项目类别:
Regulation of Vascular Smooth Muscle Cell Proliferation
血管平滑肌细胞增殖的调节
- 批准号:
7406304 - 财政年份:2008
- 资助金额:
$ 48.6万 - 项目类别:
Regulation of Vascular Smooth Muscle Cell Proliferation
血管平滑肌细胞增殖的调节
- 批准号:
7587450 - 财政年份:2008
- 资助金额:
$ 48.6万 - 项目类别:
Regulation of Vascular Smooth Muscle Cell Proliferation
血管平滑肌细胞增殖的调节
- 批准号:
7816769 - 财政年份:2008
- 资助金额:
$ 48.6万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 48.6万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 48.6万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 48.6万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 48.6万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 48.6万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 48.6万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 48.6万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 48.6万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 48.6万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 48.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists